Restoration of vision with new generation Artficial Theranostic Cornea
Restoration of vision with new generation Artficial Theranostic Cornea
批准号:
MR/T030968/1
负责人:
Hirak Patra
金额:
$174.96万
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2020
资助国家:
英国
项目状态:
未结题
起止时间:
2020 至 --
中文摘要
角膜是眼睛最外层的透明部分,它作为主要的折射元件将光线传输到视网膜,使我们看到。角膜的任何损伤或疾病导致永久性丧失其透明度,导致角膜失明。世界卫生组织在2017年的报告中估计,全球有2.53亿人患有视力障碍,其中2300万人患有单眼疾病。很明显,仅靠增加捐赠量不足以弥补捐赠角膜的短缺。更重要的是,即使供体角膜可用,患有严重病理的患者也不会从供体中受益,因为他们面临排斥供体角膜的高风险,从而需要替代方法。我将开发纳米技术辅助的促再生人工角膜(ARC),可以应对与角膜失明相关的临床挑战,以促进功能再生和恢复视力。ARC将与内置的治疗诊断(诊断兼治疗)监测系统一起开发,以识别和治疗导致移植排斥和失败的因素。新的人工角膜将具有抗感染、抗炎和细胞增殖活性。该临床前项目将收集的信息将指导未来的临床试验,并将研究转化为角膜盲患者。我提出的方法从未得到解决,在恢复视力领域是全新的,可能会彻底改变目前的角膜移植制度,可能会对英国及其他地区的生活质量产生重大影响。
英文摘要
The cornea is the outermost transparent part of the eye, which acts as the main refractive element to transmit light to the retina, giving us sight. Any damage or disease to the cornea that causes permanent loss of its transparency results in corneal blindness. The World Health Organization in their 2017 report estimated that 253 million people live with visual impairment, with 23 million suffering with one eye condition. It is clear that increasing donations alone will no way be sufficient to make up for the donor cornea shortage. More importantly, even if donor corneas were available, patients with severe pathologies would not benefit from donor as they are at high risk of rejecting the donor cornea, thereby necessitating an alternative approach. I shall develop nanotechnology assisted pro-regenerative artificial cornea (ARCs) that can combat the clinical challenges associated with corneal blindness to promote functional regeneration and restore vision. ARCs will be developed together with an in-built theranostic (diagnostic cum therapeutic) monitoring system to identify and treat factors leading to rejection and failure of the transplant. The new artificial cornea will be anti-infective, anti-inflammatory and will have cell-proliferative activity. Information will be gathered in this pre-clinical project would guide towards future clinical trials and in translation of research to patients with corneal blindness. My proposed approach is never been addressed and is completely new to the field to restore vision might revolutionise the present cornea transplantation regime could have significant impact and quality of life in UK and beyond.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.copbio.2023.102947
发表时间:
2023-05
期刊:
Current opinion in biotechnology
影响因子:
7.7
作者:
[Bapan Pramanik;M. M. Islam-M.;H. Patra]
通讯作者:
Bapan Pramanik;M. M. Islam-M.;H. Patra
DOI:
10.1016/j.tips.2022.05.001
发表时间:
2022-05
期刊:
Trends in pharmacological sciences
影响因子:
13.8
作者:
[Geyunjian H Zhu;Alex B.C. Gray;H. Patra]
通讯作者:
Geyunjian H Zhu;Alex B.C. Gray;H. Patra
Chemical Crosslinker-free Pro-regenerative Corneal Implants
不含化学交联剂的促再生角膜植入物
DOI:
--
发表时间:
2022
期刊:
影响因子:
--
作者:
[Islam M]
通讯作者:
Islam M
Crosslinker-free collagen gelation for corneal regeneration.
用于角膜再生的无交联剂胶原凝胶。
DOI:
10.1038/s41598-022-13146-9
发表时间:
2022-06-01
期刊:
SCIENTIFIC REPORTS
影响因子:
4.6
作者:
[Islam, Mohammad Mirazul, Chivu, Alexandru, AbuSamra, Dina B., Saha, Amrita, Chowdhuri, Sumit, Pramanik, Bapan, Dohlman, Claes H., Das, Debapratim, Argueso, Pablo, Rajaiya, Jaya, Patra, Hirak K., Chodosh, James]
通讯作者:
Chodosh, James
DOI:
10.1021/acsami.1c02834
发表时间:
2021-05-26
期刊:
ACS applied materials & interfaces
影响因子:
9.5
作者:
[Zhu GH, Azharuddin M, Islam R, Rahmoune H, Deb S, Kanji U, Das J, Osterrieth J, Aulakh P, Ibrahim-Hashi H, Manchanda R, Nilsson PH, Mollnes TE, Bhattacharyya M, Islam MM, Hinkula J, Slater NKH, Patra HK]
通讯作者:
Patra HK
共 8 条
Molecular strategy for developing instant nanomedicine
-
批准号:EP/Z532952/1
-
项目类别:Research Grant
-
资助金额:$19.03万
-
财政年份:2024
-
负责人:Hirak Patra
-
依托单位:
国内基金
海外基金
基于SOPC的VisionTransformer模型AI推理系统实现研究
-
批准号:2023JJ60221
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:褚杰
-
依托单位:
老年人群视障风险VISION管控模式构建与实证研究
-
批准号:71974198
-
项目类别:面上项目
-
资助金额:48.5万元
-
批准年份:2019
-
负责人:王爱平
-
依托单位: